BPL-003 for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 21 Dec 2022: Trial registered, NCT05660642
  2. 10 Feb 2023: Trial started, NCT05660642
  3. 23 May 2023: Trial registered, NCT05870540
  4. 14 Sep 2023: Trial started, NCT05870540

The trials

NCT05660642: An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

State
Under way
Phase
Phase 2
People
72 planned
Started
10 Feb 2023
Primary completion
Nov 2026
Arms
Arm A, Arm B
Results
None posted
  1. 21 Dec 2022: Trial registered
  2. 10 Feb 2023: Trial started

NCT05870540: BPL-003 Efficacy and Safety in Treatment Resistant Depression

State
Completed
Phase
Phase 2
People
196 taking part
Started
14 Sep 2023
Primary completion
28 Mar 2025
Arms
Low dose (sub-therapeutic), Medium dose, High dose, Monophasic, Biphasic
Results
Posted on the registry
  1. 23 May 2023: Trial registered
  2. 14 Sep 2023: Trial started
  3. 3 Jul 2025: Trial completed
  4. 10 Sep 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.